Clin2
NCT07145268Possibly a fitNot yet recruiting

Zinc for liver scarring in hepatitis B patients

Liver FibrosesHBV (Hepatitis B Virus)

Treatments studied

Part of Digestive system, Infections clinical trials.

This study tests whether taking zinc sulfate can help reduce liver scarring in people with chronic hepatitis B who are already on antiviral medication. If you have moderate liver scarring, you may join to see if zinc improves your liver health.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
44 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You are between 18 and 65 years old.
  • You have chronic hepatitis B and are taking antiviral medication.
  • Your liver has moderate scarring (called fibrosis stage F2 or F3).
  • You have never had liver cancer or a liver transplant.
  • You do not have HIV or hepatitis C.
  • You are not pregnant or breastfeeding.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT03770936Recruiting· Phase 3
Drugs to reduce liver scarring in chronic hepatitis C

This Phase 3 study tests medicines to see whether they can reduce liver scarring (fibrosis) in people with long-term hepatitis C. If you qualify, you may receive the study treatment and be monitored over time to see how your liver is affected.

Tanta
NCT05028829Recruiting· Phase 2
Atorvastatin to lower liver cancer risk in people with liver scarring

This trial tests whether atorvastatin (a cholesterol medicine) can lower the chance of liver cancer (HCC) in people with advanced liver scarring or cirrhosis. Participants are compared to placebo (inactive pill) while researchers track safety and cancer risk.

Boston, Massachusetts
NCT06434753Recruiting· Phase 3
Zinc supplements for stable advanced liver disease

This trial tests whether taking zinc supplements can improve the outlook for people with a certain type of advanced liver disease that is still stable (no major complications). If you have compensated advanced chronic liver disease and meet the criteria, you might be able to join.

Barcelona
NCT07169656Recruiting
Study on reducing liver cancer risk in hepatitis B patients

This study looks at how well different hepatitis B treatments help lower the risk of liver cancer. It's for people with chronic hepatitis B who are already using or starting certain antiviral or interferon therapies.

Anyang
NCT07412236Not yet recruiting· Phase 3
Long-term hydronidone for liver scarring in hepatitis B

This trial tests a long-term treatment called hydronidone for liver scarring (fibrosis) caused by chronic hepatitis B. It aims to see if the treatment can help slow or reverse liver damage in people who are already on antiviral therapy or starting treatment for the first time.

Shanghai
NCT07793695Not yet recruiting· Phase 2
Zinc supplement with immunotherapy for advanced liver cancer

This study tests different doses of zinc supplements combined with standard targeted therapy and immunotherapy for advanced liver cancer.

Hefei, Anhui

Hear when a new Liver Fibroses trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.